Impact of remote mutations on metallo-beta-lactamase substrate specificity: implications for the evolution of antibiotic resistance.
Metallo-beta-lactamases have raised concerns due to their ability to hydrolyze a broad spectrum of beta-lactam antibiotics. The G262S point mutation distinguishing the metallo-beta-lactamase IMP-1 from IMP-6 has no effect on the hydrolysis of the drugs cephalothin and cefotaxime, but significantly improves catalytic efficiency toward cephaloridine, ceftazidime, benzylpenicillin, ampicillin, and imipenem. This change in specificity occurs even though residue 262 is remote from the active site. We investigated the substrate specificities of five other point mutants resulting from single-nucleotide substitutions at positions near residue 262: G262A, G262V, S121G, F218Y, and F218I. The results suggest two types of substrates: type I (nitrocefin, cephalothin, and cefotaxime), which are converted equally well by IMP-6, IMP-1, and G262A, but even more efficiently by the other mutants, and type II (ceftazidime, benzylpenicillin, ampicillin, and imipenem), which are hydrolyzed much less efficiently by all the mutants. G262V, S121G, F218Y, and F218I improve conversion of type I substrates, whereas G262A and IMP-1 improve conversion of type II substrates, indicating two distinct evolutionary adaptations from IMP-6. Substrate structure may explain the catalytic efficiencies observed. Type I substrates have R2 electron donors, which may stabilize the substrate intermediate in the binding pocket. In contrast, the absence of these stabilizing interactions with type II substrates may result in poor conversion. This observation may assist future drug design. As the G262A and F218Y mutants confer effective resistance to Escherichia coli BL21(DE3) cells (high minimal inhibitory concentrations), they are likely to evolve naturally.
Oelschlaeger
Peter
P
Division of Biology, California Institute of Technology, Pasadena, California 91125, USA.
Mayo
Stephen L
SL
Pleiss
Juergen
J
D005075:Biological Evolution; D015195:Drug Design; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics / Q000378:metabolism; D007700:Kinetics; D009154:Mutation; D013379:Substrate Specificity / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
C409201:beta-lactamase IMP-1; D001618:beta-Lactamases
Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321-31
6109327
Antimicrob Agents Chemother. 2004 Mar;48(3):1032-3
14982802
Biochim Biophys Acta. 1994 Jun 21;1218(2):199-201
8018721
EMBO J. 1995 Oct 16;14(20):4914-21
7588620
Structure. 1996 Jul 15;4(7):823-36
8805566
Antimicrob Agents Chemother. 1999 Apr;43(4):902-6
10103197
J Biol Chem. 1999 May 28;274(22):15706-11
10336469
Antimicrob Agents Chemother. 1999 Jul;43(7):1584-90
10390207
Biochemistry. 1999 Aug 3;38(31):10013-23
10433708
FEMS Microbiol Lett. 1999 Oct 15;179(2):289-96
10518728
Biochemistry. 2002 May 28;41(21):6615-30
12022865
Biochemistry. 1999 Nov 2;38(44):14507-14
10545172
Biochemistry. 2000 Apr 18;39(15):4288-98
10757977
Antimicrob Agents Chemother. 2000 Jun;44(6):1538-43
10817705
Antimicrob Agents Chemother. 2000 Jul;44(7):1878-86
10858348
Antimicrob Agents Chemother. 2000 Aug;44(8):2023-7
10898670
Antimicrob Agents Chemother. 2000 Sep;44(9):2304-9
10952572
Biochemistry. 2000 Sep 19;39(37):11330-9
10985778
Antimicrob Agents Chemother. 2000 Nov;44(11):3003-7
11036013
Curr Opin Microbiol. 2000 Oct;3(5):489-95
11050448
Biochemistry. 2000 Nov 7;39(44):13356-64
11063572
Antimicrob Agents Chemother. 2001 Mar;45(3):660-3
11181339
Antimicrob Agents Chemother. 2001 Mar;45(3):837-44
11181369
Nat Struct Biol. 2001 Mar;8(3):238-42
11224569
FEMS Microbiol Lett. 2001 Apr 1;197(1):85-9
11287151
Biochemistry. 2001 Feb 13;40(6):1640-50
11327823
Proteins. 2001 Sep 1;44(4):448-59
11484222
Protein Sci. 2001 Dec;10(12):2556-65
11714924
FEBS Lett. 2001 Dec 14;509(3):350-4
11749954
Chembiochem. 2001 Apr 2;2(4):253-9
11828452
Biochem J. 2002 May 1;363(Pt 3):687-96
11964169
Nat Struct Biol. 2002 Jul;9(7):553-8
12042875
Antimicrob Agents Chemother. 2002 Aug;46(8):2450-7
12121917
J Comput Chem. 2002 Oct;23(13):1281-96
12210153
J Comput Chem. 2002 Dec;23(16):1587-600
12395427
BMC Biochem. 2002;3:4
11876827
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15926-31
12446841
J Mol Biol. 2003 Jan 24;325(4):651-60
12507470
Antimicrob Agents Chemother. 2003 May;47(5):1522-8
12709317
Chem Biol. 2003 Apr;10(4):319-29
12725860
Antimicrob Agents Chemother. 2003 Jul;47(7):2330-3
12821491
Protein Sci. 2003 Jul;12(7):1368-75
12824483
Protein Eng. 2003 May;16(5):341-50
12826725
Biochemistry. 2003 Aug 5;42(30):8945-56
12885227
J Antimicrob Chemother. 2003 Oct;52(4):583-90
12951335
J Bacteriol. 1991 Aug;173(15):4611-7
1856163